ATE.TO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 Apr 2024 @ 15:59):

Stats
Today's Volume	167 044
Average Volume	133 843
Market Cap	15.53M
EPS	$0 ( 2024-02-12 )
Next earnings date	( $0 ) 2024-06-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.840
ATR14	$0.00700 (2.37%)

ANTIBE THERAPEUTICS INC Correlation

10 Most Positive Correlations
SPG.TO	0.852
HPS-A.TO	0.843
PHYS.TO	0.841
XSQ.TO	0.841
TD-PFK.TO	0.812
AKU.TO	0.811

10 Most Negative Correlations
ECN-PC.TO	-0.848

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ANTIBE THERAPEUTICS INC Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.370

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0800

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.0951

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.110

Financial Reports:

No articles found.

ANTIBE THERAPEUTICS INC

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.